Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UI95: Variant p.Val85Glu

Mitotic spindle assembly checkpoint protein MAD2B
Gene: MAD2L2
Feedback?
Variant information Variant position: help 85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Glutamate (E) at position 85 (V85E, p.Val85Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to medium size and acidic (E) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In FANCV; drastically reduced protein abundance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 85 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 211 The length of the canonical sequence.
Location on the sequence: help QDTLHCVKPLLEKNDVEKVV V VILDKEHRPVEKFVFEITQP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         QDTLHCVKPLLEKNDVEKVVVVILDKEHRPVEKFVFEITQP---------------------------------------------

Mouse                         QDTLHCVKPLLEKNDVEKVVVVILDKEHRPVEKFVFEITQP

Rat                           QDTLHCVKPLLEKNDVEKVVVVILDKEHRPVEKFVFEITQP

Bovine                        QDTLHCVKPLLEKNDVEKVVVVILDKEHRPVEKFVFEITQP

Chicken                       QDTLHCVKPLLEKNDVEKVVVVILDKEHHPVERFVFEITQP

Xenopus laevis                QDTLHCVKPLIEKNDVEKVVVVILDKEHHPVERFVFEIAQP

Xenopus tropicalis            QDTLHCVKPLIEKNDVEKVVVVILDKEHHPVERFVFEIAQP

Zebrafish                     QDTLHCVKPLIEKNEAEKVVVVIMNKEHHPVERFVFEISQP

Slime mold                    SNSIDSLKPHFLKDTIEKISLTILNKYDKPIEKFIFEISSL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 211 Mitotic spindle assembly checkpoint protein MAD2B
Domain 13 – 203 HORMA
Region 21 – 155 Mediates interaction with REV1 and REV3L and homodimerization
Beta strand 80 – 88



Literature citations
Biallelic inactivation of REV7 is associated with Fanconi anemia.
Bluteau D.; Masliah-Planchon J.; Clairmont C.; Rousseau A.; Ceccaldi R.; Dubois d'Enghien C.; Bluteau O.; Cuccuini W.; Gachet S.; Peffault de Latour R.; Leblanc T.; Socie G.; Baruchel A.; Stoppa-Lyonnet D.; D'Andrea A.D.; Soulier J.;
J. Clin. Invest. 126:3580-3584(2016)
Cited for: INVOLVEMENT IN FANCV; VARIANT FANCV GLU-85; CHARACTERIZATION OF VARIANT FANCV GLU-85;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.